{"id":391145,"date":"2016-05-02T00:00:00","date_gmt":"2016-05-02T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneid0002-2016-biopharma-gram-negative-infections-unmet-need-habp-vabp-gram-negative-infections-us-eu-2016\/"},"modified":"2026-04-24T05:27:06","modified_gmt":"2026-04-24T05:27:06","slug":"unneid0002-2016-biopharma-gram-negative-infections-unmet-need-habp-vabp-gram-negative-infections-us-eu-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneid0002-2016-biopharma-gram-negative-infections-unmet-need-habp-vabp-gram-negative-infections-us-eu-2016\/","title":{"rendered":"Gram-Negative Infections | Unmet Need | HABP\/VABP Gram-Negative Infections | US\/EU | 2016"},"content":{"rendered":"<p>Hospital-acquired and ventilator-associated bacterial pneumonia (HABP\/VABP) are serious hospital-treated infections associated with high rates of multi-drug resistant (MDR) bacteria, including carbapenem-resistant organisms (CROs) (e.g., carbapenemase-producing Enterobacteriaceae and MDR A. baumannii and P. aeruginosa), as well as significant morbidity and mortality. Although several therapies in late-stage clinical development are active against these CROs, developers have faced difficulty in conducting HABP\/VABP trials as a result of changes in and misalignment between the FDA\u2019s and EMA\u2019s clinical trial guidelines for this indication. Nonetheless, significant opportunity remains for antibiotic products with efficacy against drug-resistant HABP\/VABP, including HABP\/VABP due to CROs. Such therapies are poised to command premium prices in the GNI market.<\/p>\n","protected":false},"template":"","class_list":["post-391145","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hospital-treated-infections","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391145\/revisions"}],"predecessor-version":[{"id":394268,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391145\/revisions\/394268"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}